Senores Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Senores Pharmaceuticals Ltd reported a 8.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 53.1%.
• Its expenses for the quarter were up by 8.8% QoQ and 38.1% YoY.
• The net profit increased 9.2% QoQ and increased 104.1% YoY.
• The earnings per share (EPS) of Senores Pharmaceuticals Ltd stood at 7.96 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Senores Pharmaceuticals Ltd is a company operating in the pharmaceutical industry. The organization is involved in the production and distribution of pharmaceutical products. However, specific details about the company's main products, services, or recent major developments are not available in the provided data. The pharmaceutical industry is known for its focus on research and development, regulatory approval processes, and market competition. Any additional information regarding recent trends, strategic initiatives, or business transformations for Senores Pharmaceuticals Ltd is not specified in the given data.

Revenue

For the quarter ending in Q4FY26, Senores Pharmaceuticals Ltd reported a total income of ₹192.86 crores, reflecting a quarter-over-quarter (QoQ) increase of 8.1% from ₹178.34 crores in Q3FY26. Year-over-year (YoY), the total income has grown significantly by 53.1% from ₹125.98 crores in Q4FY25. This substantial year-over-year growth in revenue indicates a considerable expansion in the company's income generation capabilities over the past year, which can be attributed to various factors such as increased sales, expansion into new markets, or introduction of new products.

Profitability

The company recorded a profit before tax (PBT) of ₹47.40 crores in Q4FY26, marking a 6.3% QoQ rise from ₹44.60 crores reported in Q3FY26. YoY, the PBT more than doubled with a 129.2% increase from ₹20.68 crores in Q4FY25. After accounting for taxes, the profit after tax (PAT) for Q4FY26 stood at ₹36.67 crores, up by 9.2% QoQ from ₹33.58 crores and by 104.1% YoY from ₹17.97 crores. The earnings per share (EPS) increased to ₹7.96, reflecting the same growth rates as PAT. The tax amount decreased slightly by 2.6% QoQ to ₹10.73 crores but increased significantly by 295.9% YoY from ₹2.71 crores. This indicates a higher effective tax rate over the year.

Operating Metrics

Total expenses for Senores Pharmaceuticals Ltd in Q4FY26 were ₹145.46 crores, which represented an 8.8% increase from the ₹133.74 crores spent in Q3FY26 and a 38.1% rise from ₹105.30 crores in Q4FY25. This increase in expenses, both QoQ and YoY, reflects the company's operational scale-up possibly to support increased production or expansion activities. The profit margins have improved YoY, evidenced by the higher proportional increase in total income compared to total expenses. However, the data provided does not include specific operating metrics such as return on assets or equity, making it challenging to calculate certain financial ratios without additional information.